Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976258 · ClinicalTrials.gov registry record
Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV
A clinical trial, sponsored by MetroHealth Medical Center.
- Completed
- Registry status
- 190
- Enrollment target
NCT03976258: Completed study, sponsored by MetroHealth Medical Center.
NCT03976258 is a clinical trial that has completed, run by MetroHealth Medical Center. The registered enrollment target is 190 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03976258 has completed, sponsored by MetroHealth Medical Center.
- COMPLETED
- Registry status
- 190 participants
- Enrollment target
Study Summary
Despite the advent of safer HIV therapies, high levels of markers of systemic inflammation and increased cardiovascular risk threaten the well-being of individuals living with HIV and present a significant challenge for HIV providers. These risks may be accentuated in HIV-infected individuals who are active intravenous drug users (IVDU); however, this population has been specifically excluded from prior studies assessing immune activation and cardiovascular risk in people living with HIV. In this study, the investigators will specifically target HIV-infected participants who are active IVDU, and co-enroll a control group of HIV-infected participants who never used IV drugs. The investigators will study the specific alterations in immune activation and several mechanisms felt to be potential drivers of immune activation outside of the IVDU population, namely gut integrity alteration, microbial translocation, and oxidized lipids. The investigators will also study the effect of IVDU on markers of arterial inflammation and vascular function. Importantly, the investigators will study the reversibility of immune activation, gut dysfunction, and cardiovascular markers after cessation of IVDU, and to that effect, compare strategies for IVDU cessation-buprenorphine/naloxone versus methadone or vivitrol maintenance treatment.
Primary Outcome
soluble marker of monocyte activation
Interventions
- DRUG Methadone
- DRUG Naltrexone Injection
- DRUG buprenorphine/naloxone
- DRUG Heroin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2022-12-31 |
What the finished NCT03976258 record still lists
NCT03976258 is an observational study that tracks outcomes without assigning an intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Methadone is the first listed.
NCT03976258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03976258 about?
NCT03976258 is a clinical study titled "Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV". Despite the advent of safer HIV therapies, high levels of markers of systemic inflammation and increased cardiovascular risk threaten the well-being of individuals living with HIV and present a significant challenge for HIV providers. These risks may be accentuated in HIV-infected individuals who ar...
What is the current status of trial NCT03976258?
This trial is currently completed. The enrollment target is 190 participants. The study started on 2017-07-14. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03976258?
The interventions under investigation include: Methadone (DRUG), Naltrexone Injection (DRUG), buprenorphine/naloxone (DRUG), Heroin (DRUG).
Who is sponsoring clinical trial NCT03976258?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI